Publications
- BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia2018 | First Faculty of Medicine, Central Library of Charles University
- Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy2018 | First Faculty of Medicine
- Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment2017 | First Faculty of Medicine, Faculty of Science, Faculty of Medicine in Hradec Králové
- Dasatinib - účinná léčba chronické myeloidní leukemie a plánované těhotenství2017 | First Faculty of Medicine
- Termination of the treatment in chronic myeloid leukemia - possi bility of stopping the tyrosine kinase inhibitors2017 | First Faculty of Medicine
- Interferon-alpha Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients2016 | First Faculty of Medicine, Faculty of Science, Third Faculty of Medicine
- Current approach for chronic myeloid leukemia treatment with tyrosin kinase inhibitors2016 | First Faculty of Medicine
- Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase2015 | First Faculty of Medicine
- Imatinib - The New Perspective in the Anticancer Therapy2004 | First Faculty of Medicine
- Interna2020 | First Faculty of Medicine, Second Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen
Loading network view...